Personalized immunotherapy of advanced breast cancer by autologous iPSCs-derived NK cells
Advancing Breast Cancer Treatment Through Personalized Immunotherapy: An International Clinical Trial
Breast cancer remains the most prevalent cancer among women worldwide, accounting for over 2.3 million new cases and more than 685,000 deaths annually. While early-stage breast cancer is often treatable, metastatic breast cancer (MBC) continues to pose significant therapeutic challenges. Resistance to conventional therapies, tumor heterogeneity, and systemic toxicity limit the effectiveness of current treatment options.
In recent years, immunotherapy has emerged as a transformative approach in oncology, harnessing the body’s own immune system to target and eliminate cancer cells. Among these strategies, Natural Killer (NK) cells have shown particular promise due to their innate ability to recognize and destroy tumor cells without prior sensitization. However, sourcing and expanding functional NK cells for clinical use remains a key hurdle.
To address this challenge, a pioneering international clinical trial has been launched:
A Clinical Trial to Evaluate the Effects of Autologous Induced Pluripotent Stem Cell-Derived Natural Killer Cells in Personalized Treatment of Patients with Advanced Metastatic Breast Cancer
This Phase I study explores the safety and therapeutic potential of NK cells derived from autologous induced pluripotent stem cells (iPSC-NK) in patients with advanced metastatic breast cancer. By generating NK cells from the patient’s own reprogrammed cells, the approach aims to minimize immune rejection and enhance anti-tumor efficacy.
- Key Highlights of the Study:
- Personalized Cell Therapy: Autologous iPSC-derived NK cells tailored to each patient
- International Collaboration: Conducted under the umbrella of the International Center for Personalized Medicine (P7 Medicine)
- Regulatory Registration: Listed on hPSCreg and IRCT
This trial represents a significant step toward integrating stem cell technology and immunotherapy in the fight against metastatic breast cancer. It reflects a broader commitment to developing ethical, effective, and personalized treatment strategies through global scientific collaboration.
Link of study: https://hpscreg.eu/browse/trial/91
P7-ONCOVAX-B™, novel anticancer vaccin for breast cancer
The International Center for Precision Medicine (P7 Medicine), is proud to announce a unique investment opportunity in the development of P7-ONCOVAX-B™, a next-generation targeted vaccine designed to revolutionize breast cancer therapy.
Why Breast Cancer: Breast cancer remains one of the most pressing global health challenges, claiming over 680,000 lives annually. Despite advances in surgery, chemotherapy, and hormone therapy, many patients still face relapse, resistance, and debilitating side effects. There is an urgent need for safer, more precise, and long-lasting solutions.
What Makes P7-ONCOVAX-B™ Different? P7-ONCOVAX-B™ is a synthetic vaccine that activates the immune system to selectively target cancer cells—without harming healthy tissue. This signal is only recognized by the immune system when presented by cancer cells, triggering a powerful and focused immune response.
Key Advantages:
- Precision Targeting: Attacks cancer cells while sparing healthy ones
- Immune Memory Activation: Offers long-term protection against recurrence
- Safety First: Avoids the toxicity of conventional treatments
- Versatile Platform: Potential to expand to other cancer types
Investment Opportunity We are seeking €2 million in strategic funding to complete preclinical studies and prepare for Phase 1 clinical trials within the next 18 months. This funding will accelerate:
- Final formulation and safety validation
- Regulatory preparation and trial design
- Expansion of manufacturing capabilities
- Strategic partnerships with clinical centers
Why Invest Now?
- Backed by a proven team of international scientists and clinicians
- Positioned at the intersection of immunotherapy and precision medicine
- Strong potential for licensing, co-development, and global market entry
- Social impact: contributing to a safer future for millions of women
Join Us Be part of a transformative journey in cancer care. For investment inquiries and partnership discussions, please contact:
Email: Khodayari@icpm.center
Phone: +49-179-2051555